Update on commercial licensing deals

RNS Number : 8916L

Benchmark Holdings PLC

11 September 2019

 

11 September 2019

Benchmark Holdings plc

("Benchmark" or the "Company")

Update on commercial licensing deals for non-core animal vaccines

Further to the Q3 Trading Update issued on 12 August 2019, the Company provides an update on the timing of the commercial licensing deals for its non-core animal vaccines.

Due to delays in discussions with third parties, a commercial licensing agreement is now not expected to be completed by the end of the Group's financial year ending 30 September 2019. A further announcement will be made in due course.

The Company is accelerating its programme of disposals and structural efficiencies and will provide an update on progress at its Q4 Trading Update in November.

Enquiries

For further information, please contact:
Benchmark Holdings plc	Tel:  [phone]
Peter George, Chairman Malcolm Pye, CEO
Ivonne Cantu, Investor Relations
Numis (Broker and NOMAD)	Tel:  [phone]
James Black, Freddie Barnfield, Freddie Naylor-Leyland
MHP Communications	Tel:  [phone]

Katie Hunt / Reg Hoare / Alistair de Kare-Silver                                             [e-mail]

About Benchmark 
Benchmark's mission is to enable food producers to improve their sustainability and profitability.

We bring together biology and technology, to develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (artemia), sea lice treatments, training and data management tools. Find out more at www.benchmarkplc.com

 

END

 

 

UPDBCGDCUSBBGCG